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Salvage therapy for relapsed testicular cancer
Nabil Adra and Lawrence H. Einhorn
Substantial advances have been made in the 
treatment of testicular cancer and these have been 
among the great achievements in modern medicine. 
The introduction and refinement of cisplatin-based 
combination chemotherapy revolutionized the treatment 
of germ-cell tumors (GCT) and patients who once had 
a dismal prognosis are now curable even in the presence 
of metastatic disease.[1] Despite these advances, 20% 
of patients receiving first-line chemotherapy require 
some form of salvage therapy. Patients who relapse with 
anatomically confined disease can be cured by salvage 
surgery.[2] The vast majority of relapsed patients, 
however, will have disseminated disease and are treated 
with salvage standard-dose or high-dose chemotherapy 
(HDCT). Standard-dose salvage chemotherapy consists 
of cisplatin-based regimens with drugs not previously 
used: etoposide-ifosfamide-cisplatin (VIP), vinblastine-
ifosfamide-cisplatin (VeIP), or paclitaxel-ifosfamide-
cisplatin (TIP). HDCT with a carboplatin-etoposide 
backbone followed by bone marrow transplant (BMT) 
was first investigated at Indiana University in 1986. In 
1996, BMT was replaced by peripheral-blood stem-cell 
transplant (PBSCT) allowing for more rapid engraftment 
and hence fewer delays in delivering a second course 
of HDCT. With this regimen, cures were achieved in 
the second-line, third-line, or further setting.[3, 4] To 
our knowledge, there have been no randomized studies 
demonstrating superiority of one form of salvage 
chemotherapy over another (standard-dose vs. HDCT) 
nor are there studies comparing one HDCT regimen to 
another.
In a series of 364 consecutive patients with relapsed 
GCT treated at Indiana University from 2004-2014, 
HDCT plus PBSCT achieved cures in 60% of patients.
[5] 94% of patients received the planned 2 courses of 
HDCT, each consisting of carboplatin 700 mg/m2 plus 
etoposide 750 mg/m2 on days -5,-4, -3 followed by stem-
cell infusion on day 0. Remission rates were higher when 
HDCT was utilized as initial salvage vs. ≥3rd line therapy 
(63% vs. 49%). Notably, patients with relapsed seminoma 
had a 90% cure rate. Cures were also achieved in patients 
with poor prognostic features: platinum refractory 
defined as progression ≤4 weeks after first-line platinum-
based chemotherapy (33%), primary mediastinal non-
seminomatous GCT (PMNSGCT) (23%), and progressive 
brain metastasis at initiation of HDCT (40%). There were 
9 treatment-related deaths (2.5%) with 6 occurring ≤30 
days from completion of HDCT. Secondary leukemia 
developed in 5 patients. 
The choice of initial salvage chemotherapy for 
relapsed GCT remains unsettled. In our opinion, patients 
who experience relapse after initial chemotherapy require 
multi-disciplinary expertise and should be referred to 
centers of testicular cancer excellence. Although there are 
no phase 3 studies demonstrating the superiority of one 
approach over another, a large multi-national retrospective 
analysis including 1,594 patients with relapsed GCT was 
published in 2011.[6] This study included patients with 
varied prognostic features and heterogeneous treatment 
regimens; results showed superior outcomes with HDCT 
vs. standard-dose chemotherapy (56% decreased risk of 
progression) translating into an overall survival in all 
prognostic subgroups except the low-risk category. The 
difference in cure rates was most pronounced in the very 
high-risk group: 27% in HDCT vs. 3% in standard-dose 
chemotherapy. An ongoing multi-national randomized 
phase 3 trial (TIGER) is investigating HDCT with the 
TI-CE (paclitaxel+ifosfamide-high-dose carboplatin 
and etoposidex3) vs. standard-dose chemotherapy with 
TIPx4 as initial salvage (ClinicalTrials.gov number, 
NCT02375204). 
At Indiana University, our preferred approach is to 
use tandem HDCT with carboplatin-etoposide plus PBSCT 
for most patients as second-line chemotherapy. There 
are special considerations in certain patient populations. 
(1) For patients who relapse with anatomically confined 
disease, salvage surgery is our preferred approach. When 
performed by experienced surgeons, this has potential for 
cure with significantly less long-term morbidity compared 
to salvage chemotherapy.[2] (2) Patients with late relapse 
(>2 years after initial platinum-based chemotherapy) have 
marginal benefit from salvage standard-dose or HDCT and 
our preferred approach is surgical resection if feasible. 
The optimal treatment for patients with multifocal 
unresectable late relapse remains unknown. (3) Patients 
with PMNSGCT have inferior outcomes compared to 
their testicular primary counterparts with higher chance 
of relapse after first-line and salvage therapy. While 
initial salvage results in PMNSGCT were disappointing, 
switching from BMT to PBSCT allowed for more rapid 
delivery of the second course of HDCT and improved 
outcomes.[4, 5] (4) The management of patients with 
progressive brain metastases at the time of relapse is 
challenging with no uniform treatment recommendations. 
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Options include chemotherapy, stereotactic or whole 
brain irradiation, surgery, or multimodality approach. 
Our experience demonstrates that patients with relapsed 
GCT and progressive brain metastases, including those 
with prior loco-regional therapy, are curable with HDCT 
and PBSCT.[7] Whole brain irradiation is seldom used 
and our preference is for stereotactic therapy, if needed. 
(5) Relapsed patients with malignant transformation 
of teratoma have worse prognosis and optimal salvage 
therapy is not well defined.[8] (6) Relapsed patients with 
platinum-refractory disease have poor prognosis and our 
approach is to proceed directly to salvage HDCT without 
prior standard-dose chemotherapy. With this approach, 
33% of patients with relapsed platinum-refractory patients 
achieve cures.[5] Although the choice of salvage therapy 
for relapsed GCT is controversial, we believe there are 
some patients who are only potentially curable by HDCT 
plus PBSCT. Patients with high risk features: platinum-
refractory, PMNSGCT, or progressive brain metastases, 
should be evaluated at tertiary care centers for expeditious 
institution of salvage treatment.
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